KYTX 240816 10.00C (KYTX240816C10000) Stock Options, News & Quotes

US OptionsDetailed Quotes

KYTX240816C10000

Watchlist

0.65
0.000.00%

15min DelayClose Jul 26 15:59 ET

0.80High0.50Low

Intraday

5D
Daily

News

Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40
Moomoo NewsJul 17 21:32 ET · Ratings
Leerink Partners Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Announces Target Price $48
Moomoo NewsJul 17 12:31 ET · Ratings
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
Zacks Jul 16 09:05 ET
Express News | HC Wainwright & Co. Reiterates Neutral on Kyverna Therapeutics, Maintains $8 Price Target
BenzingaJul 16 07:58 ET
Kyverna (KYTX) Sees Pre-Market Surge After Regulatory Milestone
Stocks TelegraphJul 16 07:49 ET
Bank Of America, Morgan Stanley And Other 3 Stocks To Watch Heading Into Tuesday
BenzingaJul 16 03:08 ET

Comments

SometimezInTheGreen

Jul 16 13:55

I like the uptrend today!

$Kyverna Therapeutics(KYTX.US)$

Jaguar8

Jul 15 15:06

NEWS

$Kyverna Therapeutics(KYTX.US)$
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient ...